Advertisement

Taris Biomedical, a Lexington life sciences company developing combination drug-device products, has taken in $18.3 million in a Series B funding round led by new investor Third Rock Ventures. Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners all returned to participate in the financing.

The company is focused on developing a treatment for bladder diseases. The funding will support its lead product, Lidocaine Releasing Intravesical System (LiRIS), in later-stage clinical trials, Taris CEO Sarma Duddu said in a news release today.

SOURCE

Advertisement
Advertisement